Recall Register

Food, drugs, devices › Mylan Institutional, Inc. (d.b.a. UDL Laboratories)

Drug recall: Diltiazem HCl Extended-release Capsules, USP 120 mg, 80 capsules, 8 blister cards of 10 capsules each per carton, Rx Onl

FDA enforcement event 80802 · Class III · initiated 14 Aug 2018 · status Terminated · terminated 26 Jun 2020

DrugVoluntary: Firm initiated1 product recordRockford, IL

FDA enforcement event 80802 is a drug recall by Mylan Institutional, Inc. (d.b.a. UDL Laboratories) of Rockford, IL, initiated 14 Aug 2018 and classified Class III, with 1 product record.

FDA defines Class III as a situation in which use of or exposure to a violative product is not likely to cause adverse health consequences. 29% of the 367 drug enforcement events initiated in 2018 carry the same class.

Status: Terminated, terminated 26 Jun 2020. Initiation: voluntary: firm initiated. Mylan Institutional, Inc. (d.b.a. UDL Laboratories) has 16 enforcement events on this register, with a median of 1 product record per event.

Recall classification reflects the relative degree of health hazard. Text in quotation marks is FDA's. openFDA export dated 28 Sep 2026.

Recalling firm

Mylan Institutional, Inc. (d.b.a. UDL Laboratories), Rockford, IL.

Reason for recall

"Failed Impurities/Degradation Specifications; out of specification results for related compound per the manufacturer"

Distribution

"Nationwide USA"

Product records

Recall numberProductQuantityClassStatusReport date
D-1112-2018Diltiazem HCl Extended-release Capsules, USP 120 mg, 80 capsules, 8 blister cards of 10 capsules each per carton, Rx Only, Manufactured by: Mylan Pharmaceuticals Inc., Morgantown, WV. NDC 51079-947-08408 cartonsClass IIITerminated29 Aug 2018

Context

29%of 2018 drug events are Class III367 events that year
1product record in this eventfirm median: 1
16events on this register for the firm

Other enforcement events for Mylan Institutional, Inc. (d.b.a. UDL Laboratories)

InitiatedProduct (first record)TypeClassRecords
1 Apr 2022Esomeprazole Magnesium Delayed-Release Capsules, USP 20 mg, packaged in Unit Dose Blister Cards of 6 (10 cards of 6 CapsDrugClass II2
18 Jan 2019Alprazolam Tablets, USP, 0.25 mg, 10x10 per carton, Rx Only, Manufactured for: Mylan Pharmaceuticals Inc., Morgantown, WDrugClass II1
1 May 2018Loxapine Capsules, USP 25 mg, packaged in 100 Unit Dose Capsules, Rx only, Manufactured by Mylan Pharmaceuticals Inc. MoDrugClass II2
21 Mar 2017Atorvastatin Calcium Tablets, 10 mg*, 100-count Unit Dose Tablets (10 x 10) per carton, Rx only, Manufactured by: Mylan DrugClass II1
27 Jan 2017Mirtazapine Tablets, USP, 45 mg. Rx only, 100 Tablets (10 X 10). Manufactured by: Mylan Pharmaceuticals Inc, Morgantown,DrugClass II1
28 Sep 2016Clonazepam Tablets, USP, 0.5 mg, packaged in a)100- count unit dose box of 10 x 10 blister cards (NDC 51079-881-20) and DrugClass III2
28 Jan 2016Clonazepam Tablets, USP, 0.5 mg, 100-count carton, Rx only, Manufactured by Mylan Pharmaceuticals Inc., Morgantown, WV, DrugClass III1
2 Nov 2015Meclizine Hydrochloride Tablets, USP, 25 mg Tablets, Packaged in 10 x 10 Tablet Blister Pack Packages, Rx Only. ManufactDrugClass III1
26 Mar 2015Fexofenadine Hydrochloride Tablets, USP 60 mg, Allergy, Non-Drowsy, Antihistamine, 100 tablets (10 X 10) per UD Cartons,DrugClass III1
3 Jul 2014Diltiazem HCl Extended-release Capsules, USP, 120 mg, packaged in 80 Capsules (8 x 10) blister cards per carton, Rx onlyDrugClass III1

All 16 events for Mylan Institutional, Inc. (d.b.a. UDL Laboratories)

Questions and answers

Why was this drug recalled?

FDA's record gives the reason for recall as: "Failed Impurities/Degradation Specifications; out of specification results for related compound per the manufacturer"

What does Class III mean?

FDA classifies recalls by relative degree of health hazard. Class III is a situation in which use of or exposure to a violative product is not likely to cause adverse health consequences.

Where was the product distributed?

FDA's distribution pattern field reads: "Nationwide USA"

Is the recall still ongoing?

FDA lists the status as Terminated; the termination date is 26 Jun 2020. "Terminated" means FDA has determined that all reasonable efforts to remove or correct the product have been made.

Where does this data come from?

openFDA enforcement reports (food, drug and device), CC0, export dated 28 Sep 2026. Text in quotation marks is FDA's. The FDA enforcement report linked above is authoritative.

Provenance

Source: openFDA drug enforcement reports (CC0), export dated 28 Sep 2026; records grouped by FDA event number. The class shown for the event is the most severe class among its records. Errors in processing are corrected at the next build; see corrections.